Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,898 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Effect of Drug Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
View directory record Official record
Conditions
Drug Interaction
Interventions
Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

NCT03712540
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278, Rifampin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Nov 15, 2026, 9:02 AM EST
Completed No phase listed Observational

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

NCT00803920
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
16 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Warfarin and PA21

NCT01477424
View directory record Official record
Conditions
Drug Interaction Potentiation
Interventions
PA21, Warfarin
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Ketamine Infusions for PTSD and Treatment-Resistant Depression

NCT02577250
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic
Interventions
Ketamine
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Nov 15, 2026, 9:02 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

A Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers

NCT07710820
View directory record Official record
Conditions
Smoking, Tobacco
Interventions
31237616, 31237617, 31237571, 31237581
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
1,060 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
9
States / cities
Brandon, Florida • Coral Springs, Florida • Aurora, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 4 Interventional

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

NCT00384904
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir/Ritonavir, Atazanavir/Ritonavir + Famotidine, Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Voorhees Township, New Jersey • Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 4 Interventional Results available

The Effects of ADHD Medication (TEAM) Study

NCT02293655
View directory record Official record
Conditions
ADHD
Interventions
OROS-Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04753697
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Nov 15, 2026, 9:02 AM EST
Active, not recruiting No phase listed Observational Results available

CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

NCT03933826
View directory record Official record
Conditions
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
570 participants
Timeline
2019 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional

Digoxin Drug-Drug Interaction With Lurasidone HCl

NCT01082289
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects

NCT01657825
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of S- and R-warfarin, Pharmacodynamics of Warfarin, Healthy Volunteers
Interventions
Isavuconazole, Warfarin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2012 · Synced Nov 15, 2026, 9:02 AM EST
Withdrawn Phase 2 Interventional

Study of Panitumumab in the Treatment of Carcinoid Syndrome

NCT01172717
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Panitumumab
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Nov 15, 2026, 9:02 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

NCT01045863
View directory record Official record
Conditions
Healthy
Interventions
PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 2Phase 3 Interventional

NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00061776
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Cocaine During Phendimetrazine Maintenance

NCT02522325
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Phendimetrazine, Cocaine, Placebo
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Nov 15, 2026, 9:02 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Reactions to E-cigs and Alcohol

NCT03449017
View directory record Official record
Conditions
Alcohol Abuse, Nicotine Dependence Tobacco Product
Interventions
E-cig use
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Nov 15, 2026, 9:02 AM EST
Not listed Phase 1 Interventional

Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI

NCT01355991
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 2 Interventional

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

NCT04661514
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Psilocybin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Efavirenz

NCT01098526
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Nov 15, 2026, 9:02 AM EST
Active, not recruiting Not applicable Interventional

Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial

NCT07442578
View directory record Official record
Conditions
Childhood Cancer Survivors, Cardiotoxicity, Cardiovascular Diseases, Anthracycline-induced Cardiotoxicity
Interventions
HIIT Exercise Program, MICT Exercise Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With a Potential Alzheimer's Disease Compound

NCT00726726
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2008 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

NCT04470778
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986256, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Nov 15, 2026, 9:02 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate

NCT03644576
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ozanimod, Pseudoephedrine, ozanimod placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Nov 15, 2026, 9:02 AM EST